{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"description":"Number of Participants with wound dehiscence, postop wound infection (requiring antibiotics), and fistula formation","groups":[{"description":"Patients receive IDO1 inhibitor BMS-986205 PO QD. Beginning week 2, patients also receive nivolumab IV over 30 minutes on day 1. Treatment repeats for up to 5 weeks in the absence of disease progression or unacceptable toxicity. Patients showing a treatment response receive IDO1 inhibitor BMS-986205 PO QD for 4 additional weeks and receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 10. Those without a treatment response after 5 weeks undergo surgery within 7 days.\n\nNivolumab: Given IV\n\nIDO1 Inhibitor BMS-986205: Given PO\n\nTherapeutic Conventional Surgery: Undergo Surgery\n\nQuestionnaire Administration: Ancillary studies","id":"OG000","title":"Arm A: BMS986205 + Nivolumab"},{"description":"Patients receive nivolumab IV over 30 minutes on day 1 in the absence of disease progression or unacceptable toxicity. Patients showing treatment response after 4 weeks receive nivolumab IV over 30 minutes on day 1, then undergo surgery at week 9. Those without a treatment response after 4 weeks undergo surgery within 7 days.\n\nNivolumab: Given IV\n\nTherapeutic Conventional Surgery: Undergo Surgery\n\nQuestionnaire Administration: Ancillary studies","id":"OG001","title":"Arm B: Group I - Nivolumab Only"},{"description":"Data from Contemporaneous Study 10237 (NCT03238365) participants who received Nivolumab alone prior to surgery is used as a historical controls under the current window of treatment (WOT), to bolster the control group.","id":"OG002","title":"Arm C: Group II - Nivolumab Only"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Number of Participants With Wound Dehiscence","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}